Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 19/20 | 0.59 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.57 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2316508 | 1.00 | CHRM3 (0.59) | CHRM3CHRM2CHRM1 | |
| SCHEMBL3652795 | 0.86 | CHRM3 (0.64) | CHRM3CHRM2CHRM1 | |
| SCHEMBL1997752 | 0.86 | CHRM3 (0.64) | CHRM3CHRM2CHRM1 | |
| SCHEMBL1995616 | 0.85 | CHRM3 (0.55) | CHRM3CHRM2CHRM1 | |
| SCHEMBL1997705 | 0.84 | CHRM3 (0.57) | CHRM3CHRM2CHRM1 | |
| SCHEMBL1996426 | 0.84 | CHRM3 (0.53) | CHRM3CHRM2CHRM1 | |
| SCHEMBL1997977 | 0.83 | CHRM3 (0.56) | CHRM3CHRM2CHRM1 | |
| SCHEMBL2001707 | 0.83 | CHRM3 (0.58) | CHRM3CHRM2CHRM1 | |
| SCHEMBL2003627 | 0.83 | CHRM3 (0.58) | CHRM3CHRM2CHRM1 | |
| SCHEMBL2000025 | 0.83 | CHRM3 (0.58) | CHRM3CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8785633-B2 | Guanidine-containing compounds useful as muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-07-22 | — | — | US | claimed |
| CN-101796026-B | Guanidine-containing compounds useful as muscarinic receptor antagonists | THERAVANCE INC | 2013-10-23 | — | — | CN | claimed |
| US-20130267706-A1 | GUANIDINE-CONTAINING COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC | 2013-10-10 | — | — | US | claimed |
| US-8338424-B2 | Guanidine-containing compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2012-12-25 | — | — | US | claimed |
| US-20120219509-A1 | GUANIDINE-CONTAINING COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2012-08-30 | — | — | US | claimed |
| EP-2197841-B1 | GUANIDINE-CONTAINING COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE INC (US) | 2011-11-02 | — | — | EP | claimed |
| US-7960385-B2 | Guanidine-containing compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2011-06-14 | — | — | US | claimed |
| CN-101796026-A | Guanidine-containing compounds useful as muscarinic receptor antagonists | THERAVANCE INC | 2010-08-04 | — | — | CN | claimed |
| US-20090069335-A1 | Guanidine-containing compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. | 2009-03-12 | — | — | US | claimed |
| US-8785633-B2 | Guanidine-containing compounds useful as muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-07-22 | — | — | US | disclosed |
| CN-101796026-B | Guanidine-containing compounds useful as muscarinic receptor antagonists | THERAVANCE INC | 2013-10-23 | — | — | CN | disclosed |
| US-20130267706-A1 | GUANIDINE-CONTAINING COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC | 2013-10-10 | — | — | US | disclosed |
| US-8338424-B2 | Guanidine-containing compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-20120219509-A1 | GUANIDINE-CONTAINING COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2012-08-30 | — | — | US | disclosed |
| US-20110319448-A1 | GUANIDINE-CONTAINING COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2011-12-29 | — | — | US | disclosed |
| EP-2197841-B1 | GUANIDINE-CONTAINING COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE INC (US) | 2011-11-02 | — | — | EP | disclosed |
| US-8039489-B2 | Guanidine-containing compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2011-10-18 | — | — | US | disclosed |
| US-7960385-B2 | Guanidine-containing compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| CN-101796026-A | Guanidine-containing compounds useful as muscarinic receptor antagonists | THERAVANCE INC | 2010-08-04 | — | — | CN | disclosed |
| US-20090069335-A1 | Guanidine-containing compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267706-A1 | GUANIDINE-CONTAINING COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM3, CHRM5, CHRM1 | CHRM3 1/4885CHRM2 4/4885CHRM1 3/4885 |
| US-20110319448-A1 | GUANIDINE-CONTAINING COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM3, CHRM5, CHRM1 | CHRM3 1/4885CHRM2 4/4885CHRM1 3/4885 |
| US-20120219509-A1 | GUANIDINE-CONTAINING COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM3, CHRM5, CHRM1 | CHRM3 1/4885CHRM2 4/4885CHRM1 3/4885 |
| US-20090069335-A1 | Guanidine-containing compounds useful as muscarinic receptor antagonists | CHRM3, CHRM5, CHRM1 | CHRM3 1/4885CHRM2 4/4885CHRM1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.